John Douglas Hudson MD

Neurology•Austin, TX

Sleep Medicine

Founder of Austin Neurological Clinic

Join to View Full Profile

5508 Parkcrest DrSte 310Austin, TX 78731
Phone+1 512-420-9900
Fax+1 512-420-9944

Education & Training

University of Iowa Hospitals and ClinicsResidency, Neurology, 1964 - 1967
Methodist Health System DallasInternship, Transitional Year, 1963 - 1964
University of Texas Medical Branch School of MedicineClass of 1963

Certifications & Licensure

TX State Medical License 1963 - 2027
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Lifetime Achievement Award Texas Neurological Society, 2020

Clinical Trials

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve Start of enrollment: 2014 Mar 01
Terminated
Phase 2
The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN) Start of enrollment: 2013 Nov 01
Unknown status
Not Applicable
12-Week Study of Plecanatide for CIC (The National CIC3 Study) Start of enrollment: 2014 Apr 01
Completed
Phase 3
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Start of enrollment: 2014 Jul 07
Completed
Phase 2
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Start of enrollment: 2015 Sep 01
Completed
Phase 2
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy Start of enrollment: 2017 Mar 14
Completed
Phase 3
Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain Start of enrollment: 2021 Oct 19
Active, not recruiting
Phase 2, Phase 3
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Start of enrollment: 2004 Oct 01
Completed
Phase 3
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome Start of enrollment: 2004 Oct 01
Completed
Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine Start of enrollment: 2021 Jun 30
Completed
Phase 3
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens Start of enrollment: 2022 Mar 04
COMPLETED
PHASE4
Roles: Contact
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH Start of enrollment: 2022 Dec 28
COMPLETED
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

19 citations
Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
Terri E. Weaver, Christopher L. Drake, Heike Benes, Thomas Stern, James Maynard
Annals of the American Thoracic Society. 2020-07-31
13 citations
Pharmacokinetics of rotigotine transdermal system in adolescents with idiopathic restless legs syndrome (Willis–Ekbom disease)
Jan-Peer Elshoff, John D. Hudson, Daniel L. Picchietti, Keith Ridel, Arthur S. Walters
Sleep Medicine. 2017-04-01
11 citations
Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
Diego Garcia-Borreguero, Richard P. Allen, John D. Hudson, Elisabeth Dohin, Frank Grieger
Current Medical Research and Opinion. 2016-01-02

Press Mentions

What Is the Best Humidity Level for My CPAP Machine?October 13th, 2021
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep ApnoeaJuly 22nd, 2023
Incannex Submits Key Application to US FA for IHL-42X for Treatment of Obstructive Sleep ApnoeaJuly 25th, 2023

Professional Memberships

American Academy of Sleep Medicine - AASM
Fellow

John Douglas Hudson MD

Dr. Hudson is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.